Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
43
IRD Quote, Financials, Valuation and Earnings
Last price:
$1.16
Seasonality move
:
-10.47%
Day range:
$1.08 - $1.13
52-week range:
$0.65 - $2.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.38x
P/B ratio:
13.17x
Volume:
138.5K
Avg. volume:
687.3K
1-year change:
-42.27%
Market cap:
$66.8M
Revenue:
$11M
EPS (TTM):
-$2.10
Analysts' Opinion
-
Consensus RatingOpus Genetics has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.00, Opus Genetics has an estimated upside of 435.71% from its current price of $1.12.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $1.12.
Fair Value
-
According to the consensus of 3 analysts, Opus Genetics has 435.71% upside to fair value with a price target of $6.00 per share.
IRD vs. S&P 500
-
Over the past 5 trading days, Opus Genetics has overperformed the S&P 500 by 0.84% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Opus Genetics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Opus Genetics has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Opus Genetics reported revenues of $4.4M.
Earnings Growth
-
Opus Genetics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Opus Genetics reported earnings per share of -$0.24.
Enterprise value:
25M
EV / Invested capital:
--
Price / LTM sales:
2.38x
EV / EBIT:
--
EV / Revenue:
1.83x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.87x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-131.97%
Net Income Margin (TTM):
-429.42%
Return On Equity:
-220.73%
Return On Invested Capital:
-220.73%
Operating Margin:
-227.21%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | $19M | $13.7M | $1.7M | $4.4M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | $18.6M | -$12.1M | -$36.3M | -$7.7M | -$9.9M | |
| EBITDA | $18.7M | -$10.4M | -$57.8M | -$7.1M | -$6.8M | |
| Diluted EPS | $0.83 | -$0.49 | -$2.10 | -$0.29 | -$0.24 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $12.1M | $20.5M | $45.4M | $51.8M | $47.9M | |
| Total Assets | $12.1M | $20.5M | $45.4M | $51.8M | $48.2M | |
| Current Liabilities | $2.3M | $3.2M | $4.2M | $5.8M | $24.3M | |
| Total Liabilities | $2.3M | $3.2M | $4.2M | $5.8M | $43.1M | |
| Total Equity | $9.8M | $17.3M | $41.3M | $46.1M | $5.1M | |
| Total Debt | -- | $215K | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $16.8M | -$3.2M | -$28.9M | -$5.7M | -$9M | |
| Cash From Investing | -- | -- | $1.2M | -- | -- | |
| Cash From Financing | $2.9M | $11.4M | $22.3M | $2.4M | $20.5M | |
| Free Cash Flow | $16.8M | -$3.2M | -$28.9M | -$5.7M | -$9M | |
IRD
Sector
Market Cap
$66.8M
$34.4M
Price % of 52-Week High
51.38%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-18.66%
-1.01%
1-Year Price Total Return
-42.27%
-37.36%
Beta (5-Year)
-0.018
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.09
200-day SMA
Buy
Level
$1.07
Bollinger Bands (100)
Buy
Level
0.86 - 1.08
Chaikin Money Flow
Buy
Level
762.6K
20-day SMA
Buy
Level
$1.01
Relative Strength Index (RSI14)
Buy
Level
63.84
ADX Line
Buy
Level
31.24
Williams %R
Sell
Level
-12.053
50-day SMA
Buy
Level
$1.00
MACD (12, 26)
Buy
Level
0.30
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Neutral
Level
1.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.5592)
Sell
CA Score
(Annual)
Level (-5.5152)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (9.0282)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Stock Forecast FAQ
In the current month, IRD has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IRD average analyst price target in the past 3 months is $6.00.
-
Where Will Opus Genetics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Opus Genetics share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About Opus Genetics?
Analysts are divided on their view about Opus Genetics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Opus Genetics is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Opus Genetics's Price Target?
The price target for Opus Genetics over the next 1-year time period is forecast to be $6.00 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IRD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Opus Genetics is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IRD?
You can purchase shares of Opus Genetics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Opus Genetics shares.
-
What Is The Opus Genetics Share Price Today?
Opus Genetics was last trading at $1.16 per share. This represents the most recent stock quote for Opus Genetics. Yesterday, Opus Genetics closed at $1.12 per share.
-
How To Buy Opus Genetics Stock Online?
In order to purchase Opus Genetics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
